Key Takeaways
- • TPG is exploring a sale of Lyric, a medical claims software provider, at a valuation of approximately $5 billion, with JPMorgan advising on the process as of September 9, 2026.
- • Lyric generates roughly $250 million in annual EBITDA, implying a valuation multiple of approximately 20x EBITDA—a significant valuation for healthcare software assets.
- • TPG originally acquired ClaimsXten for $2.2 billion in 2022, which was previously part of Change Healthcare; Lyric appears to represent the evolution or integration of that healthcare software platform.
- • The potential sale of Lyric will serve as a high-profile market test for payment integrity and healthcare software valuations in the current private equity exit environment.
- • A successful transaction at the proposed valuation would represent a substantial return for TPG and reflect strong demand from buyers in the healthcare IT sector.
Summary
TPG is actively exploring the sale of Lyric, a healthcare software company focused on medical claims processing, at an estimated valuation of approximately $5 billion. JPMorgan has been engaged to advise the private equity firm on the transaction, according to sources familiar with the matter. The sale process represents a strategic exit for TPG from a key healthcare technology asset during a period of elevated M&A activity in the sector.
Lyric's financial profile underscores the appeal of the asset to potential acquirers. The company generates approximately $250 million in annual EBITDA, which yields an implied valuation multiple of roughly 20x EBITDA at the $5 billion asking price. This elevated multiple reflects the strategic value of healthcare software platforms—particularly those with established customer relationships among insurers and claims administrators—and the competitive intensity surrounding healthcare IT acquisitions in the current market.
TPG's involvement in healthcare software extends back to its 2022 acquisition of ClaimsXten for approximately $2.2 billion. That asset was divested from Change Healthcare as part of regulatory considerations at the time. Lyric's operations appear to build upon or represent the strategic evolution of TPG's healthcare claims processing portfolio. The current sale exploration suggests TPG is capitalizing on favorable market conditions and demonstrated buyer demand for healthcare software platforms with recurring revenue streams.
The potential transaction carries broader market significance. A successful sale at the proposed $5 billion valuation would serve as a prominent benchmark for healthcare software valuations and payment integrity solutions in the current environment. The outcome may influence pricing expectations and buyer appetite for comparable healthcare IT assets. For institutional investors tracking private equity deployment in healthcare IT, this transaction represents an important data point on exit multiples and the sustainability of high valuations in the sector.
Lyric's financial profile underscores the appeal of the asset to potential acquirers. The company generates approximately $250 million in annual EBITDA, which yields an implied valuation multiple of roughly 20x EBITDA at the $5 billion asking price. This elevated multiple reflects the strategic value of healthcare software platforms—particularly those with established customer relationships among insurers and claims administrators—and the competitive intensity surrounding healthcare IT acquisitions in the current market.
TPG's involvement in healthcare software extends back to its 2022 acquisition of ClaimsXten for approximately $2.2 billion. That asset was divested from Change Healthcare as part of regulatory considerations at the time. Lyric's operations appear to build upon or represent the strategic evolution of TPG's healthcare claims processing portfolio. The current sale exploration suggests TPG is capitalizing on favorable market conditions and demonstrated buyer demand for healthcare software platforms with recurring revenue streams.
The potential transaction carries broader market significance. A successful sale at the proposed $5 billion valuation would serve as a prominent benchmark for healthcare software valuations and payment integrity solutions in the current environment. The outcome may influence pricing expectations and buyer appetite for comparable healthcare IT assets. For institutional investors tracking private equity deployment in healthcare IT, this transaction represents an important data point on exit multiples and the sustainability of high valuations in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.